On March, 8. Investors wait ObsEva SA (NASDAQ:OBSV) to announce its quarterly earnings, as reported by Faxor. Analysts forecast 2.08 % diference or $-0.47 from the $-0.48 EPS from 2018. 11.90 % negative EPS growth is what Wall Street’s forecasts after $-0.42 reported EPS last quarter. OBSV is hitting $12.47 during the last trading session, after decreased 5.39%.ObsEva SA has 81,875 shares volume, 41.13% up from normal. OBSV is uptrending and has moved 58.14% since March 1, 2018. OBSV outperformed by 58.14% the S&P500.

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders.The firm is valued at $567.10 million. The firm intends to develop products for treating endometriosis, uterine fibroids, and preterm labor, as well as for enhancing clinical pregnancy and live birth rates in women undergoing IVF.Currently it has negative earnings. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to improve clinical pregnancy and live birth rates in women undergoing IVF; and OBE022, an oral and selective prostaglandin F2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of pregnancy.

For more ObsEva SA (NASDAQ:OBSV) news released recently go to: Globenewswire.com, Globenewswire.com, Globenewswire.com, Benzinga.com or Seekingalpha.com. The titles are as follows: “ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis – GlobeNewswire” released on June 18, 2018, “ObsEva SA to Participate in November Investor Conferences – GlobeNewswire” on November 07, 2018, “ObsEva SA to Participate in JP Morgan Healthcare Conference January 7-10, 2019 – GlobeNewswire” with a publish date: January 02, 2019, “Daily Biotech Pulse: IntelliPharmaCeutics Generic Antidepressant Gets FDA Nod, GW Pharma Earnings – Benzinga” and the last “An In-Depth Look At ObsEva – Seeking Alpha” with publication date: October 17, 2018.